<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01645930</url>
  </required_header>
  <id_info>
    <org_study_id>C16013</org_study_id>
    <secondary_id>U1111-1155-5943</secondary_id>
    <secondary_id>HKUCTR-1593</secondary_id>
    <nct_id>NCT01645930</nct_id>
  </id_info>
  <brief_title>Phase 1 Pharmacokinetic Study of Oral IXAZOMIB Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
  <official_title>A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) Plus Lenalidomide and Dexamethasone in Asian Patients With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 1 study is to characterize the Pharmacokinetic (PK) and
      tolerability of Oral IXAZOMIB when administered in combination with lenalidomide and
      dexamethasone in adult Asian patients with Relapsed and/or Refractory Multiple Myeloma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 17, 2012</start_date>
  <completion_date type="Actual">April 10, 2017</completion_date>
  <primary_completion_date type="Actual">April 4, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters including, but not limited to Cmax, Tmax and AUC 0-last</measure>
    <time_frame>Cycle 1 - Day 1,2, 3, 5, 8, 15, 16, 17, 19, 22; Cycle 2- Day 1</time_frame>
    <description>To characterize the PK in plasma of oral IXAZOMIB in combination with lenalidomide and dexamethasone in Asian patients with RRMM</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events (AEs), Serious Adverse Events (SAEs), assessments of clinical laboratory values, and vital sign measurements</measure>
    <time_frame>Recorded from the first dose of study drug through 30 days after the last dose of study drug</time_frame>
    <description>To characterize the tolerability of oral IXAZOMIB in combination with lenalidomide and dexamethasone in Asian patients with RRMM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with a response</measure>
    <time_frame>Assessed every other cycle during treatment until disease progression, approximately 1 year</time_frame>
    <description>To determine the response rate in Asian patients with RRMM upon administration of Per Oral IXAZOMIB in combination with lenalidomide and dexamethasone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>From date of documentation of a confirmed response to date of progressive disease, approximately 1 year</time_frame>
    <description>To determine the DOR in Asian patients with RRMM upon administration of oral MLIXAZOMIB in combination with lenalidomide and dexamethasone</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>IXAZOMIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IXAZOMIB+Lenalidomide+Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IXAZOMIB</intervention_name>
    <description>Patients will receive Oral IXAZOMIB (4.0 mg) on Days 1, 8, and 15; lenalidomide (25 mg) on Days 1 through 21; and dexamethasone (40mg) on Days 1, 8, 15, and 22.</description>
    <arm_group_label>IXAZOMIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female East Asian patients 18 years or older

          -  Diagnosed Multiple Myeloma according to standard criteria

          -  Measurable disease as specified in study protocol

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Patients with relapsed and/or refractory Multiple Myeloma who have received 1 to 3
             prior therapies

          -  Meet the clinical laboratories criteria as specified in the protocol

          -  Female patients who are post menopausal, surgically sterile, or agree to practice 2
             effective methods of contraception or agree to abstain from heterosexual intercourse;
             must also adhere to the guidelines of the lenalidomide pregnancy prevention program

          -  Male patients who agree to practice effective barrier contraception or agree to
             abstain from heterosexual intercourse AND must adhere to the guidelines of the
             lenalidomide pregnancy prevention program

          -  Must be able to take concurrent aspirin 325 mg daily

          -  Voluntary written consent

        Exclusion Criteria:

          -  Female patients who are lactating or pregnant

          -  Major surgery or radiotherapy within 14 days before enrollment

          -  Infection requiring systematic antibiotics within 14 days before study enrollment

          -  Central nervous system involvement

          -  Failure to have fully recovered from the effects of prior chemotherapy regardless of
             the interval since last treatment

          -  Systemic treatment with strong inhibitors of CYP1A2, strong inhibitors of CYP3A, or
             strong CYP3A inducers, or use of Ginko biloba or St. John's wort within 14 days before
             study enrollment

          -  Diagnosis of Waldenstrom's macroglobulinemia, POEMS syndrome, plasma cell leukemia,
             primary amyloidosis, myelodysplastic syndrome, or myeloproliferative syndrome

          -  Evidence of current uncontrolled cardiovascular conditions

          -  Serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to the protocol

          -  Known allergy to any of the study medications

          -  Known gastrointestinal condition or procedure that could interfere with swallowing or
             the oral absorption of tolerance of IXAZOMIB

          -  Diagnosed or treated for another malignancy within 2 years before study enrollment or
             previously diagnosed with another malignancy and have any evidence of residual disease
             with the exception of nonmelanoma skin cancer or any completely resected carcinoma in
             situ

          -  Ongoing or active systemic infection, active hepatitis B virus infect, active
             hepatitis C infection, or known human immunodeficiency virus (HIV) positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>July 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed multiple myeloma,</keyword>
  <keyword>Refractory multiple myeloma,</keyword>
  <keyword>MLN9708,</keyword>
  <keyword>Proteasome inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 20, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

